Monoclonal antibodies were highly effective in preventing severe COVID-19 before resistance developed

New data on neutralizing monoclonal antibodies (nMAbs) pose a challenge to COVID-19 researchers across the globe: The drugs were highly safe and effective at reducing the severity of COVID-19 infections—especially among unvaccinated people—but they are now not used due to in vitro drug resistance among currently circulating SARS-CoV-2 variants.

The study, published in JAMA Network Open yesterday, offers insight into how and why scientists should continue looking at nMAbs to treat current and future variants

...